New Twice-Monthly diabetes pill challenges daily treatment
NCT ID NCT07122102
Summary
This study will compare a new diabetes medication called cofrogliptin (taken once every two weeks) with an existing medication called acarbose (taken three times daily) in 200 people with type 2 diabetes who haven't tried medication before. Researchers want to see which drug works better at lowering blood sugar levels over 12 weeks and which has fewer side effects. The study will also check how the medications affect weight, insulin function, and even gut bacteria.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
He'nan Provincial People's Hospital
Zhengzhou, Henan, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.